Mode
Text Size
Log in / Sign up
Phase 3 N=460 Randomized Quadruple-blind Treatment

Establishing the Vitamin D Requirements During Lactation

Vitamin D Deficiency

Enrolled (actual)
460
Serious AEs
0.7%
Results posted
Jun 2016
Primary outcome: Primary: 25-Hydroxyvitamin D Levels for Postpartum Mother 7 Months After Delivery — 28.5; 38.0; 55.6 ng/mL

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
400 IU Vitamin D3 (cholecalciferol) (Drug); 2400 IU Vitamin D3 (cholecalciferol) (Drug); 6400 IU Vitamin D3 (cholecalciferol) (Drug)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
Medical University of South Carolina
Primary completion
Oct 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
25-Hydroxyvitamin D Levels for Postpartum Mother 7 Months After Delivery
28.5; 38.0; 55.6
SECONDARY
Maternal Health Status - Vitamin D Deficiency
22.95; 11.36; 4.69
SECONDARY
Infant Health Status - Vitamin D Deficiency
2.78; 8.11; 2.63

Summary

The purpose of this study is to determine the effectiveness and safety of maternal and infant vitamin D supplementation as a function of ethnicity and latitude in the prevention of vitamin D deficiency in the breastfeeding mother-infant pair. The findings of this study will generate important new information for health care professionals and policy makers with regard to vitamin D requirements and the potential benefit to both mother and infant

Eligibility Criteria

Inclusion Criteria

  • Mother plans to breastfeed exclusively for at least six months
  • Mother is in good health
  • Infant is 35 weeks' gestation or greater
  • Breastfeeding infant is in good health ( Level I nursery; or Level II nursery but not requiring oxygen therapy or parenteral nutrition beyond first 72 hours).

Exclusion Criteria

  • Mother does not plan to breastfeed exclusively for the first six months (plans to use formula for infant's feedings during the first six months
  • Infant has been admitted to Neonatal Intensive Care unit requiring oxygen therapy or parental nutrition beyond the first 72 hours
  • Infant is less than 35 weeks' gestation
  • Infant has been diagnosed with a congenital anomaly or abnormal chromosomal pattern
  • Mother has a history of endocrine dysfunction involving parathyroid gland, diabetes, or calcium abnormalities related to renal disease such that calcium parameters are abnormal
  • Mother has history of hypercalciuria
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00412074). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search